This highlights the need for further research to distinguish between the risk of developing an autoimmune phenotype and the risk of progressing to severe clinical manifestations like TED. While the research teams findings suggest a protective association between GLP-1 drug therapy and TED, the underlying biological pathways remain speculative
Includes collagen, elastin, fibronectin, laminins, proteoglycans, and other components
Any potential advantage must be weighed against the well characterised adverse event profile of GLP-1 receptor agonistsincluding gastrointestinal intolerance, gallbladder disease, acute pancreatitis, and other adverse eventswithin a shared, patient centred decision making process that balances individual risk against potential additive gains.1 The observed epidemiological patterns in our study are highly consistent with the known pharmacology and neurobiological mechanisms of GLP-1 receptor agonists
Some research suggests that chronic high-dose L-carnitine supplementation may increase TMAO levels via gut bacteria metabolism, and elevated TMAO has been associated with increased cardiovascular risk in observational studies